Table 3

Median affordability (days’ wages) of insulin and comparator medicines across countries

Public sectorPrivate retail pharmaciesPrivate hospitals/clinics
Median days’ wages (range)NMedian days’ wages (range)NMedian days’ wages (range)N
Insulins (10 mL 100 IU/mL)
 Short-acting human3.9 (0.3–6.8)93.7 (1.2 to 20.2)144.2 (0.7–21.7)12
 Intermediate-acting human3.6 (1.6–4.8)64.3 (1.3 to 30.4)135.0 (0.5–21.7)12
 Mixed human3.5 (0.5–6.5)82.2 (1.2 to 7.5)133.7 (1.3–22.1)11
 Rapid-acting analogue6.3 (4.9–7.4)46.6 (2.7 to 50.9)136.8 (3.1–14.0)6
 Long-acting analogue7.9 (4.5–17.3)515.6 (4.6 to 94.2)1514.3 (4.5–43.1)9
 Mixed analogue6.1 (2.8–8.8)67.9 (3.2 to 43.5)146.7 (3.3–14.0)8
Comparator medicines
 Metformin 500 mg ×90HP: 2.4 (0.1–5.2)9HP: 2.2 (0.3 to 13.4)15HP: 2.0 (0.3–7.2)13
LP: 1.3 (0.1–5.2)LP: 0.8 (0.2 to 11.2)LP: 1.2 (0.3–4.3)
 Gliclazide 80 mg ×30HP: 0.6 (0.3–2.2)4HP: 0.7 (0.5 to 2.6)8HP and LP: 1.0 (0.5–3.4)9
LP: 0.4 (0.2–0.7)LP: 0.5 (0.2 to 2.6)
 Enalapril 10 mg ×30HP: 0.6 (0.2–0.9)5HP: 0.8 (0.3 to 4.4)14HP: 1.0 (0.1–6.1)12
LP: 0.5 (0.1–0.9)LP: 0.7 (0.2 to 4.4)LP: 0.8 (0.1–6.1)
 Ceftriaxone 1 g vial ×1HP: 1.2 (0.1–3.6)8HP: 2.3 (0.1 to 8.7)14HP: 1.1 (0.1–5.1)14
LP: 0.5 (0.1–1.5)LP: 0.4 (0.1 to 0.9)LP: 0.6 (0.1–2.8)
  • HP, highest priced products; LP, lowest priced products; N, number of surveys.